Susan S Huang1, Edward Septimus2, Ken Kleinman3, Julia Moody4, Jason Hickok4, Lauren Heim5, Adrijana Gombosev5, Taliser R Avery6, Katherine Haffenreffer6, Lauren Shimelman6, Mary K Hayden7, Robert A Weinstein8, Caren Spencer-Smith4, Rebecca E Kaganov6, Michael V Murphy6, Tyler Forehand4, Julie Lankiewicz6, Micaela H Coady6, Lena Portillo7, Jalpa Sarup-Patel7, John A Jernigan9, Jonathan B Perlin4, Richard Platt6. 1. Division of Infectious Diseases, University of California Irvine School of Medicine, Irvine, CA, USA. Electronic address: sshuang@uci.edu. 2. Clinical Services Group, HCA Healthcare, Houston, TX, USA; Division of Infectious Diseases, Texas A&M College of Medicine, Houston, TX, USA; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA. 3. Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, MA, USA. 4. Nashville, TN, USA. 5. Division of Infectious Diseases, University of California Irvine School of Medicine, Irvine, CA, USA. 6. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA. 7. Division of Infectious Diseases, Rush Medical College, Chicago, IL, USA. 8. Division of Infectious Diseases, Rush Medical College, Chicago, IL, USA; Department of Medicine, Cook County Health and Hospitals System, Chicago, IL, USA. 9. Office of HAI Prevention Research and Evaluation, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Universal skin and nasal decolonisation reduces multidrug-resistant pathogens and bloodstream infections in intensive care units. The effect of universal decolonisation on pathogens and infections in non-critical-care units is unknown. The aim of the ABATE Infection trial was to evaluate the use of chlorhexidine bathing in non-critical-care units, with an intervention similar to one that was found to reduce multidrug-resistant organisms and bacteraemia in intensive care units. METHODS: The ABATE Infection (active bathing to eliminate infection) trial was a cluster-randomised trial of 53 hospitals comparing routine bathing to decolonisation with universal chlorhexidine and targeted nasal mupirocin in non-critical-care units. The trial was done in hospitals affiliated with HCA Healthcare and consisted of a 12-month baseline period from March 1, 2013, to Feb 28, 2014, a 2-month phase-in period from April 1, 2014, to May 31, 2014, and a 21-month intervention period from June 1, 2014, to Feb 29, 2016. Hospitals were randomised and their participating non-critical-care units assigned to either routine care or daily chlorhexidine bathing for all patients plus mupirocin for known methicillin-resistant Staphylococcus aureus (MRSA) carriers. The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultures attributed to participating units, measured in the unadjusted, intention-to-treat population as the HR for the intervention period versus the baseline period in the decolonisation group versus the HR in the routine care group. Proportional hazards models assessed differences in outcome reductions across groups, accounting for clustering within hospitals. This trial is registered with ClinicalTrials.gov, number NCT02063867. FINDINGS:There were 189 081 patients in the baseline period and 339 902 patients (156 889 patients in the routine care group and 183 013 patients in the decolonisation group) in the intervention period across 194 non-critical-care units in 53 hospitals. For the primary outcome of unit-attributable MRSA-positive or VRE-positive clinical cultures (figure 2), the HR for the intervention period versus the baseline period was 0·79 (0·73-0·87) in the decolonisation group versus 0·87 (95% CI 0·79-0·95) in the routine care group. No difference was seen in the relative HRs (p=0·17). There were 25 (<1%) adverse events, all involving chlorhexidine, among 183 013 patients in units assigned to chlorhexidine, and none were reported for mupirocin. INTERPRETATION: Decolonisation with universal chlorhexidine bathing and targeted mupirocin for MRSA carriers did not significantly reduce multidrug-resistant organisms in non-critical-care patients. FUNDING: National Institutes of Health.
RCT Entities:
BACKGROUND: Universal skin and nasal decolonisation reduces multidrug-resistant pathogens and bloodstream infections in intensive care units. The effect of universal decolonisation on pathogens and infections in non-critical-care units is unknown. The aim of the ABATE Infection trial was to evaluate the use of chlorhexidine bathing in non-critical-care units, with an intervention similar to one that was found to reduce multidrug-resistant organisms and bacteraemia in intensive care units. METHODS: The ABATE Infection (active bathing to eliminate infection) trial was a cluster-randomised trial of 53 hospitals comparing routine bathing to decolonisation with universal chlorhexidine and targeted nasal mupirocin in non-critical-care units. The trial was done in hospitals affiliated with HCA Healthcare and consisted of a 12-month baseline period from March 1, 2013, to Feb 28, 2014, a 2-month phase-in period from April 1, 2014, to May 31, 2014, and a 21-month intervention period from June 1, 2014, to Feb 29, 2016. Hospitals were randomised and their participating non-critical-care units assigned to either routine care or daily chlorhexidine bathing for all patients plus mupirocin for known methicillin-resistant Staphylococcus aureus (MRSA) carriers. The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultures attributed to participating units, measured in the unadjusted, intention-to-treat population as the HR for the intervention period versus the baseline period in the decolonisation group versus the HR in the routine care group. Proportional hazards models assessed differences in outcome reductions across groups, accounting for clustering within hospitals. This trial is registered with ClinicalTrials.gov, number NCT02063867. FINDINGS: There were 189 081 patients in the baseline period and 339 902 patients (156 889 patients in the routine care group and 183 013 patients in the decolonisation group) in the intervention period across 194 non-critical-care units in 53 hospitals. For the primary outcome of unit-attributable MRSA-positive or VRE-positive clinical cultures (figure 2), the HR for the intervention period versus the baseline period was 0·79 (0·73-0·87) in the decolonisation group versus 0·87 (95% CI 0·79-0·95) in the routine care group. No difference was seen in the relative HRs (p=0·17). There were 25 (<1%) adverse events, all involving chlorhexidine, among 183 013 patients in units assigned to chlorhexidine, and none were reported for mupirocin. INTERPRETATION: Decolonisation with universal chlorhexidine bathing and targeted mupirocin for MRSA carriers did not significantly reduce multidrug-resistant organisms in non-critical-care patients. FUNDING: National Institutes of Health.
Authors: Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Steven Z Kassakian; Leonard A Mermel; Julie A Jefferson; Stephen L Parenteau; Jason T Machan Journal: Infect Control Hosp Epidemiol Date: 2011-03 Impact factor: 3.254
Authors: Charles E Edmiston; Gary R Seabrook; Christopher P Johnson; Daryl S Paulson; Christopher M Beausoleil Journal: Am J Infect Control Date: 2007-03 Impact factor: 2.918
Authors: Michael W Climo; Kent A Sepkowitz; Gianna Zuccotti; Victoria J Fraser; David K Warren; Trish M Perl; Kathleen Speck; John A Jernigan; Jaime R Robles; Edward S Wong Journal: Crit Care Med Date: 2009-06 Impact factor: 7.598
Authors: A M G A de Smet; J A J W Kluytmans; B S Cooper; E M Mascini; R F J Benus; T S van der Werf; J G van der Hoeven; P Pickkers; D Bogaers-Hofman; N J M van der Meer; A T Bernards; E J Kuijper; J C A Joore; M A Leverstein-van Hall; A J G H Bindels; A R Jansz; R M J Wesselink; B M de Jongh; P J W Dennesen; G J van Asselt; L F te Velde; I H M E Frenay; K Kaasjager; F H Bosch; M van Iterson; S F T Thijsen; G H Kluge; W Pauw; J W de Vries; J A Kaan; J P Arends; L P H J Aarts; P D J Sturm; H I J Harinck; A Voss; E V Uijtendaal; H E M Blok; E S Thieme Groen; M E Pouw; C J Kalkman; M J M Bonten Journal: N Engl J Med Date: 2009-01-01 Impact factor: 91.245
Authors: Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Brian D Lewis; Kellie R Brown; Jonathan B Towne Journal: J Am Coll Surg Date: 2008-05-23 Impact factor: 6.113
Authors: Jens Hachenberg; Christian Eichler; Ellen Acis; Maximilian Mattes Auer-Schmidt; Mathias Warm; Wolfram Malter; Fabinshy Thangarajah Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: D Cal Ham; Isaac See; Shannon Novosad; Matthew Crist; Garrett Mahon; Lucy Fike; Kevin Spicer; Pamela Talley; Andrea Flinchum; Marion Kainer; Alexander J Kallen; Maroya Spalding Walters Journal: J Hosp Infect Date: 2020-04-10 Impact factor: 3.926
Authors: Vinay K Giri; Kristin G Kegerreis; Yi Ren; Lauren M Bohannon; Erica Lobaugh-Jin; Julia A Messina; Anita Matthews; Yvonne M Mowery; Elizabeth Sito; Martha Lassiter; Jennifer L Saullo; Sin-Ho Jung; Li Ma; Morris Greenberg; Tessa M Andermann; Marcel R M van den Brink; Jonathan U Peled; Antonio L C Gomes; Taewoong Choi; Cristina J Gasparetto; Mitchell E Horwitz; Gwynn D Long; Richard D Lopez; David A Rizzieri; Stefanie Sarantopoulos; Nelson J Chao; Deborah H Allen; Anthony D Sung Journal: Transplant Cell Ther Date: 2021-01-07
Authors: Xin Huang; Charlotte Hurabielle; Rebecca A Drummond; Nicolas Bouladoux; Jigar V Desai; Choon K Sim; Yasmine Belkaid; Michail S Lionakis; Julia A Segre Journal: Cell Host Microbe Date: 2020-12-31 Impact factor: 21.023